加载中
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
前收盘价
US$6.39
+US$0.21 · +3.40%
盘前
US$6.39
US$0.00 · 0.00%
10月12日 5:13 ET
盘中时间采用ET。市场数据可能有所延迟。
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
日内区间
当前US$6.39
52周区间
当前US$6.39
盘中时间采用ET。市场数据可能有所延迟。
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
日内区间
当前US$6.39
52周区间
当前US$6.39
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 702.5万 USD | 565.6万 USD |
| 销货成本 | — | 213.3万 USD | 170.7万 USD | — | — |
| 毛利 | — | −213.3万 USD | −170.7万 USD | 702.5万 USD | 565.6万 USD |
| 研究与开发 | 1.34亿 USD | 1.12亿 USD | 4821.6万 USD | 2840.2万 USD | 2585.2万 USD |
| 销售、一般及管理费用 | 3610.7万 USD | 3013.1万 USD | 1248.3万 USD | 800.7万 USD | 615万 USD |
| 营业费用 | 1.7亿 USD | 1.4亿 USD | 6069.9万 USD | 3640.9万 USD | 3200.2万 USD |
| 利息收入 | 909.4万 USD | 1535.9万 USD | 228.2万 USD | 56.5万 USD | 1000 USD |
| 利息支出 | 48.9万 USD | 14.2万 USD | 18.7万 USD | 6.5万 USD | 3000 USD |
| 折旧和摊销 | 179.9万 USD | 213.3万 USD | 170.7万 USD | 105.1万 USD | 58.6万 USD |
| 营业利润 | −1.7亿 USD | −1.43亿 USD | −6240.6万 USD | −2938.4万 USD | −2634.6万 USD |
| 净利润 | −1.61亿 USD | −1.27亿 USD | −6036.6万 USD | −2889.3万 USD | −2635万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$25.00
上涨空间 291.24%评级样本有限，仅4项
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1189.63万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM696.8万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF370.26万0.00%954亿 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM305.14万0.05%64.1亿 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO204.41万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB180.5万0.02%108.2亿 USD0.44%US$206.49+3.00%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP160.7万0.06%26.06亿 USD0.20%US$66.35+1.13%
Schwab U.S. Small-Cap ETFSCHA118.62万0.01%218.24亿 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBState Street SPDR S&P Kensho New Economies Composite ETFKOMPSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
